Cargando…
Adenosine usage during AF ablation in Europe and selected long-term findings from the ESC-EHRA EORP Atrial Fibrillation Ablation Long-Term registry
BACKGROUND: Adenosine can be used to reveal dormant pulmonary vein (PV) conduction after PV isolation (PVI). This study presents a subanalysis of real-world 1-year follow-up data from the ESC-EHRA EORP Atrial Fibrillation (AF) Ablation Long-Term registry to analyze the usage of adenosine during PVI...
Autores principales: | van Rosmalen, Frank, Delhaas, Tammo, Dagres, Nikolaos, Arbelo, Elena, Blomström-Lundqvist, Carina, Crijns, Harry J. G. M., Da Costa, Antoine, Pytkowski, Mariusz, Sharikov, Nikita, Laroche, Cécile, Tavazzi, Luigi, Brugada, Joseph, Pison, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134287/ https://www.ncbi.nlm.nih.gov/pubmed/32356163 http://dx.doi.org/10.1007/s10840-020-00744-8 |
Ejemplares similares
-
Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry
por: Ding, Wern Yew, et al.
Publicado: (2022) -
AFA-Recur: an ESC EORP AFA-LT registry machine-learning web calculator predicting atrial fibrillation recurrence after ablation
por: Saglietto, Andrea, et al.
Publicado: (2022) -
Contemporary management of atrial fibrillation and the predicted vs. absolute risk of ischaemic stroke despite treatment: a report from ESC-EHRA EORP-AF Long-Term General Registry
por: Ding, Wern Yew, et al.
Publicado: (2022) -
Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry
por: Proietti, Marco, et al.
Publicado: (2021) -
Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry
por: Proietti, Marco, et al.
Publicado: (2021)